3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Neoplasm Metastasis
2
von Hippel-Lindau Disease
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Thymus Neoplasms
1
Sarcoma, Kaposi
1
Sarcoma
1
Recurrence
1
Neuroendocrine Tumors
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Liposarcoma
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Hamartoma Syndrome, Multiple
1
Glioma
1
Glioblastoma
1
Endometrial Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Brain Neoplasms
1
Bone Neoplasms
1
Autistic Disorder
1
Astrocytoma
1
Advanced Lung Neuroendocrine Tumor
1
Interventions
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Everolimus
×
30 days
×
Clear all
No trials found.